Skip to main content

and
  1. No Access

    Article

    Prolonged use of eltrombopag in patients with severe aplastic anemia in the real world

    Eltrombopag (EPAG) can improve the efficacy of immunosuppressive therapy (IST) consisting of antithymocyte immunoglobulin (ATG) and cyclosporin in severe aplastic anemia (SAA) patients. This study explored whe...

    Ruixin Li, Ningling Wang, **ngxing Chai, Linhai Yang in Clinical and Experimental Medicine (2023)

  2. Article

    Correction to: A real‑world experience of eltrombopag plus rabbit antithymocyte immunoglobulin–based IST in Chinese patients with severe aplastic anemia

    Yuanyuan **, Ruixin Li, Shengyun Lin, **song Jia, Yan Yang in Annals of Hematology (2023)

  3. No Access

    Article

    A real-world experience of eltrombopag plus rabbit antithymocyte immunoglobulin–based IST in Chinese patients with severe aplastic anemia

    Eltrombopag (EPAG), a thrombopoietin receptor agonist, was approved for the treatment of severe aplastic anemia (SAA) combined with immunosuppressive therapy (IST). However, the effects of real-life use of low...

    Yuanyuan **, Ruixin Li, Shengyun Lin, **song Jia, Yan Yang in Annals of Hematology (2022)

  4. Article

    Open Access

    GFI1B acts as a metabolic regulator in hematopoiesis and acute myeloid leukemia

    Recent studies highlighted the role of transcription factors in metabolic regulation during hematopoiesis and leukemia development. GFI1B is a transcriptional repressor that plays a critical role in hematopoie...

    Longlong Liu, Pradeep Kumar Patnana, **aoqing **e, Daria Frank in Leukemia (2022)